We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-16.43%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$791B
AUM Growth
-$200B
Cap. Flow
-$11.4B
Cap. Flow %
-1.44%
Top 10 Hldgs %
26.42%
Holding
3,063
New
88
Increased
1,490
Reduced
1,207
Closed
101

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$3.46B
2
UNH icon
UnitedHealth
UNH
+$2.79B
3
CRM icon
Salesforce
CRM
+$2.38B
4
SHW icon
Sherwin-Williams
SHW
+$1.41B
5
PM icon
Philip Morris
PM
+$1.34B

Sector Composition

Rank Sector Weight
1 Technology 26.68%
2 Healthcare 19.49%
3 Consumer Discretionary 13.07%
4 Financials 11.17%
5 Communication Services 8.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FARM
2776
DELISTED
Farmer Brothers
FARM
$86K ﹤0.01%
18,400
TIG
2777
DELISTED
Trean Insurance Group, Inc. Common Stock
TIG
$86K ﹤0.01%
13,745
+397
+3% +$2.35K
IBIO icon
2778
iBio
IBIO
$70M
$85K ﹤0.01%
645
-41
-6% -$6.16K
AP icon
2779
Ampco-Pittsburgh
AP
$197M
$84K ﹤0.01%
21,600
INOD icon
2780
Innodata
INOD
$1.99B
$84K ﹤0.01%
17,300
-4,500
-21% -$29K
MMAT
2781
DELISTED
Meta Materials Inc. Common Stock
MMAT
$84K ﹤0.01%
811
-595
-42% -$88.8K
BRMK
2782
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$84K ﹤0.01%
12,458
+904
+8% +$6.82K
PRTY
2783
DELISTED
Party City Holdco Inc.
PRTY
$84K ﹤0.01%
63,723
+17,000
+36% +$37.6K
DHT icon
2784
DHT Holdings
DHT
$3.09B
$83K ﹤0.01%
13,461
+845
+7% +$4.96K
ASXC
2785
DELISTED
Asensus Surgical, Inc.
ASXC
$83K ﹤0.01%
209,700
-21,241
-9% -$9.48K
SCPX
2786
DELISTED
Scorpius Holdings, Inc.
SCPX
$83K ﹤0.01%
8
DRRX
2787
DELISTED
DURECT Corp
DRRX
$82K ﹤0.01%
17,128
-1,800
-10% -$8.6K
IVC
2788
DELISTED
Invacare Corporation
IVC
$82K ﹤0.01%
64,300
+6,043
+10% +$7.96K
CMAX
2789
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$82K ﹤0.01%
+750
New +$129K
INSG icon
2790
Inseego
INSG
$78M
$81K ﹤0.01%
4,272
+1,960
+85% +$50K
PRVB
2791
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$81K ﹤0.01%
20,148
+272
+1% +$1.29K
CRDF icon
2792
Cardiff Oncology
CRDF
$80.9M
$80K ﹤0.01%
36,500
+15,020
+70% +$25.2K
PPSI
2793
Pioneer Power Solutions
PPSI
$33.1M
$80K ﹤0.01%
27,800
VTGN icon
2794
VistaGen Therapeutics
VTGN
$11.8M
$79K ﹤0.01%
2,978
+32
+1% +$1.13K
FTCI icon
2795
FTC Solar
FTCI
$40M
$78K ﹤0.01%
2,163
-608
-22% -$24.1K
STTK icon
2796
Shattuck Labs
STTK
$749M
$78K ﹤0.01%
19,300
-2,316
-11% -$8.39K
SYRS
2797
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$78K ﹤0.01%
8,092
+4
+0% +$37
YEXT icon
2798
Yext
YEXT
$585M
$77K ﹤0.01%
16,111
+1,265
+9% +$7.03K
EPM icon
2799
Evolution Petroleum
EPM
$135M
$76K ﹤0.01%
14,000
-5,400
-28% -$36.3K
MRNS
2800
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$76K ﹤0.01%
15,600
+4,417
+39% +$26.9K

Similar funds

T. Rowe Price Associates's Q2 2022 Portfolio in Review

As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
  • T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
  • T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
  • T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
  • T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
  • T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.